Siemens Healthineers to Invest EUR 350 Million in New Campus Forchheim

Siemens HealthineersSiemens Healthineers is planning to expand its location in Forchheim in response to the continuing strong demand for medical imaging devices, in particular for CT scanners and x-ray applications. The new "Siemens Healthineers Campus" will consist of an ultra-modern factory for medical components and a new R&D and logistics center alongside the existing facilities. Siemens Healthineers will be investing around EUR 350 million in this project over the next five years. Construction at the site is scheduled to begin in 2020.

"With its IPO, Siemens Healthineers set itself the clear ambition to shape the future of healthcare. This forward-looking investment into the Forchheim campus is a critical milestone paying into this direction. It reinforces our claim to generate sustainable, profitable growth based on the strength of our market and technology leadership as well as demonstrating our commitment to our home market Germany," said Michael Sen, Supervisory Board Chairman of Siemens Healthineers.

"This is one of the biggest investments ever made by Siemens Healthineers. Construction of this ultra-modern campus in Forchheim demonstrates our commitment to meeting the strong demand for imaging technology and will help us secure our position as an innovation and market leader," stated Bernd Montag, CEO of Siemens Healthineers.

Production of x-ray tube assemblies and generators for x-ray machines is planned to begin in 2023. The new facilities will consist of 47,000 square meters, and the existing production for these components in Erlangen, with around 700 employees, will be relocated to Forchheim. The new state-of-the-art facility will make production less costly, enhance the quality of the products and provide adequate capacities for further growth.

The company currently has separate facilities for x-ray machines and generators in the neighboring city of Erlangen. Expansion of the production capacities at the existing locations is not possible due to a lack of space. Siemens Healthineers is therefore also expanding its Forchheim location by purchasing more land. The Forchheim city council already approved the preliminary planning application in October 2018. Buildings being vacated in Erlangen will be used for other purposes by Siemens Healthineers and Siemens AG in the future.

In addition to the production and administration buildings at the site, Siemens Healthineers plans to construct a test and development center at the Forchheim Campus. Construction of a car park for employees on the site is also planned. The pace of innovation and development and exploitation of synergy potential are to be accelerated and enhanced through the close interaction of the two production facilities and direct proximity to the business units. For example, CT scanners are to be built in Forchheim, thus shortening the supply channels for the x-ray tube assemblies and generators used in these products to a minimum in the future. Having the business units in the immediate vicinity will also improve coordination in the development and production of the equipment.

The headquarters of both the Diagnostic Imaging (DI) and Advanced Therapy (AT) business segments are currently located in Forchheim. The future Campus will consist of the existing production and administration buildings, along with the new development and production facilities for x-ray tube assemblies and generators.

X-ray tube assemblies and x-ray generators are medical components used in CT scanners, for example. The x-ray tube assemblies contain the x-ray tubes that generate the x-ray radiation. X-ray generators include all the components required for operation of the x-ray tubes. They also generate and regulate the high voltage required for operation of the x-ray tubes.

About Siemens Healthineers

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.

In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide.

Most Popular Now

Merck and Tencent Announce Collaboration…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public...

Merck Granted U.S. Patent for Novel Comb…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates...

The European Health Catapult Program for…

Through dedicated sessions, a group of international top-level investors, key healthcare leaders and industry stakeholders work closely together challenging 40+ ambitious startups to optimize their business plan and strengthen their...

Applications Now Open for Pioneering Dig…

The Yorkshire & Humber AHSN (Academic Health Science Network), in partnership with mHabitat, announces that applications for the 2019 Propel@YH digital health accelerator programme are now open. Propel@YH has been...

Flagship Axe the Fax Trust Rolls out Hyb…

Leeds Teaching Hospitals NHS Trust (LTHT), the organisation at the forefront of the national Axe the Fax campaign, is implementing an electronic fax solution to tackle its last remaining machines...

First EU Citizens Using ePrescriptions i…

The first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a...

Boehringer Ingelheim (Canada) Ltd. and I…

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology...

Final Report: Provision of a Market Stud…

The aim of the study is to examine the telemedicine market in Europe and to understand the factors that determine its development. The analysis maps telemedicine applications and solutions, and...

Open Access Drug Development Tools Featu…

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of...

The NHS Long Term Plan: Cracking the Da …

Opinion Article by Prof. Michael Thick, Chief Medical Officer, Chief Clinical Information Officer, IMS MAXIMS Reading the NHS Long Term Plan this week, I had a definite sense of déjà vu...

Big Data Approach Shown to be Effective …

Researchers at Rensselaer Polytechnic Institute who developed a blood test to help diagnose autism spectrum disorder have now successfully applied their distinctive big data-based approach to evaluating possible treatments. The...

Highland Marketing Advisory Board Respon…

The first meeting of Highland Marketing's newly expanded advisory board discussed the NHS Long Term Plan and what will be needed to make it a success. Structural change, leadership, investment...